# Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation

> **NCT07221760** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **n-Lorem Foundation** · enrollment: 1 (estimated)

## Conditions studied

- Dentatorubral-Pallidoluysian Atrophy

## Interventions

- **DRUG:** nL-ATN1-001

## Key facts

- **NCT ID:** NCT07221760
- **Lead sponsor:** n-Lorem Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-11-06
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 1 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221760, "Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07221760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*